SRPT
Sarepta Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.73
+3.68%Sep 30, 2026, 12:30 UTC
Sarepta Therapeutics presented new data at the 31st Annual Congress of the World Muscle Society showing clinically meaningful functional benefit of ELEVIDYS (delandistrogene moxeparvovec) in older ambulatory patients with Duchenne muscular dystrophy.
Source:Sep 25, 2026, 12:30 UTC
Sarepta Therapeutics announced it will present new data from its Duchenne muscular dystrophy treatment portfolio, including a late-breaking poster on delandistrogene moxeparvovec, at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan, on Sept. 29 - Oct. 3.
Source:Sep 24, 2026, 12:30 UTC
Sarepta Therapeutics announced it will present new data from its neuromuscular portfolio, including first results from the Phase 4 ENDURE Study, at the 27th Annual Neuromuscular Study Group Scientific Meeting on Sept. 25-27, 2026, in San Antonio, Texas.
Source:Sep 23, 2026, 20:13 UTC
REGENXBIO Inc. signed a settlement agreement with Sarepta Therapeutics under which Sarepta will pay $39.0 million and all ongoing patent litigation over the Patents-in-Suit will be terminated, with a covenant not to sue over AAVrh74-based capsid products including ELEVIDYS.
Sep 21, 2026, 22:15 UTC
Judge Brian E. Murphy of the U.S. District Court for the District of Massachusetts dismissed with prejudice a putative securities class action against Sarepta Therapeutics and certain executives over alleged misstatements about its gene therapies.
Source:Sep 8, 2026, 17:02 UTC
Shares of Dyne Therapeutics and Sarepta Therapeutics fell on Tuesday after Novartis' muscle disease drug failed a trial, raising investor concerns about similar therapies.
Source:Aug 27, 2026, 19:00 UTC
Sarepta Therapeutics shares rose 12% on Thursday, rebounding from July lows, as investors looked ahead to upcoming clinical data.
Source:Aug 24, 2026, 16:02 UTC
Kahn Swick & Foti, LLC initiated an investigation into the officers and directors of Sarepta Therapeutics, Inc. regarding potential breaches of fiduciary duties.
Aug 13, 2026, 07:38 UTC
Bank of America Corp DE increased its stake in Sarepta Therapeutics, Inc. by 26.6% during the second quarter of 2026, acquiring an additional 450,336 shares to hold 2,145,926 shares, as disclosed in a recent SEC filing.
Source:Aug 6, 2026, 01:31 UTC
Sarepta Therapeutics reported its financial results for the quarter ended June 2026.
Jul 27, 2026, 13:19 UTC
Sarepta Therapeutics appointed Michael Severino as its new CEO, effective July 28, succeeding Doug Ingram who is retiring.
Source:Jun 30, 2026, 12:30 UTC
The FDA accepted for filing the supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53 submitted by Sarepta Therapeutics.
Source:Jun 4, 2026, 00:00 UTC
Sarepta Therapeutics elected Douglas S. Ingram, Hans Wigzell, Kathryn J. Boor, Michael Chambers, and Deirdre Connelly as directors on June 4, 2026.